NCIC CLINICAL TRIALS GROUP

BREAST

DISEASE SITE COMMITTEE MEETING

AGENDA

Hilton Montréal Bonaventure, Montréal, Québec
Saturday, April 29, 2006 - 8:30 a.m. - 4:15 p.m.
Room: Westmount

Chairs: K. Pritchard & T. Whelan

8:30 a.m. **WELCOME**
Introductions
Comments

8:30 a.m. **CLOSED TRIALS**
MA.5 M. Levine
MA.12 V. Bramwell
MA.14 M. Pollak/K. Pritchard
MA.17, MA.17L, MA.17B P. Goss
MA.21 M. Burnell/M. Levine
MA.23 K. Pritchard
MA.24 Trans HERA K. Gelmon/K. Pritchard
MA.28 K. Gelmon

9:30 a.m. **OPEN TRIALS**
MA.17R P. Goss
MA.20 T. Whelan
MA.22 M. Trudeau
MA.26 E. Rakovitch/T. Whelan
MA.27, MA.27B, MA.27D P. Goss

10:15 a.m. **COFFEE BREAK**

10:30 a.m. **CTSU TRIALS – OPEN AND CLOSED**
MAC.1 (CALGB 49907/CTSU 49907) (Elderly) D. Grenier
MAC.3 (ECOG E2100) (Taxol +/- Avastin) T. Shenkier
MAC.4 (IBCSG 24-02/SOFT) B. Walley
MAC.5 (IBCSG 25-02/TEXT) B. Walley
MAC.6 (IBCSG 26-02/PERCHE) B. Walley
MAC.7 (SWOG S0226) (AI vs AI + F) T. Vandenberg
MAC.8 (NSABP 37) M. Clemons
MAC.9 (SWOG S0307) Bisphosphonate M. Clemons
MAC.10 (SWOG S0347) (Ongoing Herceptin) D. Mirchandani
MAC.11 (SWOG 0221) (Adjuvant Chemo in high risk) J. Latreille

*continued*
11:20 p.m. **NEW / PENDING TRIALS**

- MA.29
- SWOG S0221-Metrononic Dose Dense Therapy
- Node Negative Gene Signature Trial (TailorX)

**PREVENTION TRIALS**

- MAP.1
- MAP.2
- MAP.3
- CTG-SCRN Communication Survey of Patient-Professional Communication for Health Professionals

12:00 p.m. **LUNCH**

1:30 p.m. **PROPOSED TRIALS**

- 1:30 p.m. AI/Radiation Therapy Trial
- 1:50 p.m. SUPREMO Trial
- 2:10 p.m. Faslodex vs AI After Five Years of Tamoxifen
- 2:30 p.m. Chemotherapy/AI Timing
- 2:50 p.m. New Adjuvant Her2 Positive Trial
- 3:10 p.m. Metformin

3:30 p.m. **IND TRIALS**

- IND.163
- IND.164

3:40 p.m. **INTERGROUP + CTSU**

(+ Announcement: Neoadjuvant Meeting – April 2007 – Bethesda)

3:50 p.m. **TISSUE/SERUM COLLECTIONS/CORRELATIVE TRIALS**

4:00 p.m. **GENERAL GROUP STRATEGIES**

4:10 p.m. **BRIEF EXECUTIVE MEETING**

4:15 p.m. **ADJOURNMENT**